KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Research & Development (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Research & Development for 15 consecutive years, with $27.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 2.86% to $27.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.2 million through Dec 2025, down 2.35% year-over-year, with the annual reading at $106.2 million for FY2025, 2.35% down from the prior year.
  • Research & Development for Q4 2025 was $27.8 million at Supernus Pharmaceuticals, down from $29.4 million in the prior quarter.
  • The five-year high for Research & Development was $29.4 million in Q3 2025, with the low at $15.0 million in Q1 2021.
  • Average Research & Development over 5 years is $22.6 million, with a median of $22.4 million recorded in 2023.
  • The sharpest move saw Research & Development tumbled 30.53% in 2021, then skyrocketed 48.79% in 2023.
  • Over 5 years, Research & Development stood at $21.1 million in 2021, then fell by 15.68% to $17.8 million in 2022, then soared by 31.35% to $23.3 million in 2023, then rose by 22.7% to $28.6 million in 2024, then dropped by 2.86% to $27.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $27.8 million, $29.4 million, and $22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.